the Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

385 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-05-20

Study Completion Date

2021-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ACE2) through scRNA-seq data analyses. The study identified the organs that are at risk and are vulnerable to SARS-CoV-2 infection. Therefore, cells with ACE2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. These results suggest that oral mucosa could be a target of SARS-CoV-2 infection

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oral Manifestation in Patients With SARS-CoV2 Infection.

NCT04821986

SARS-CoV Infection

COMPLETED

Oral Manifestation of COVID 19 Patient: A Cross Sectional Study on Egyptian Population

NCT04391881

Oral Health and COVID 19

UNKNOWN

Oral Manifestations of Coronavirus Disease 2019(COVID-19) :a Multicentre Study

NCT04487665

Covid19

UNKNOWN

Prevalence of Oral Lesions in COVID-19 Patients

NCT04917549

Oral Lesions COVID-19 Angiotensin-converting Enzyme 2

COMPLETED

Prevalence of Oral Mucosal Alterations in Mucocutaneous Ocular Disorders

NCT03679988

Oral Disease Muco-Cutaneo-Ocular Syndrome

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The oral cavity is particularly susceptible to viral infection with several viruses such as herpes simplex virus, cytomegalovirus and Zika virus because of its structures, especially salivary glands and soft tissues . Moreover, oral mucosa can be affected by secondary pathological process of a bacterial or fungal nature due to viral immunosuppression. The oral cavity could be considered a "biological barometer" of both viral infection and viral immunosuppression advancement .

The SARS-Cov2 virus was identified in china at the end of 2019 and spread worldwide causing a global pandemic. Current research showed that SARS-Cov2 virus invades human cells via the receptor angiotensin-converting enzyme 2 (ACE2) through scRNA-seq data analyses. The study identified the organs that are at risk and are vulnerable to SARS-CoV-2 infection. Therefore, cells with ACE2 receptor distribution may become host cells for the virus and cause inflammatory response in related organs and tissues, such as the tongue mucosa and salivary glands. These results suggest that oral mucosa could be a target of SARS-CoV-2 infection .

Although many authors reported the presence of oral lesion associated with SARS-CoV2 infection, the prevalence of the oral manifestation and the range of oral manifestation are still unknown. Further studies are necessary to better understanding of the symptoms of the SARS-CoV2 virus in order to faster detection. A multidisciplinary team following the patients could be the key in treatment of the infection and faster recovery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

SARS-CoV2 Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A diagnosis of SARS-CoV2 with PCR.
* Age range from 18-60 years old
* Hospital admission not more than 10 days

Exclusion Criteria

* Pregnancy or contraceptive pills
* Lactation
* Any auto-immune disease that could affect the oral mucosa
* On any neoplastic therapy.
* Uncontrolled diabetes.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No